List view / Grid view
Xofluza® offers the first novel mechanism of action for an…
Xofluza® offers the first novel mechanism of action for an influenza antiviral to be approved by the European Commission in almost 20 years.
Glofitamab for relapsed or refractory large B-cell lymphoma has been…
Glofitamab for relapsed or refractory large B-cell lymphoma has been granted priority review by the US Food and Drug Administration (FDA).
Roche’s Vabysmo® (faricimab) has been approved in Europe as a…
Roche’s Vabysmo® (faricimab) has been approved in Europe as a four-monthly treatment for wet age-related macular degeneration and diabetic macular oedema.
New data demonstrates the long-term safety and efficacy of Evrysdi®…
New data demonstrates the long-term safety and efficacy of Evrysdi® (risdiplam) in a broad population of people with spinal muscular atrophy (SMA).
Roche's gantenerumab is an anti-amyloid beta antibody developed for subcutaneous…
Roche's gantenerumab is an anti-amyloid beta antibody developed for subcutaneous administration in Alzheimer’s disease patients.
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were…
All five pre-symptomatic babies with spinal muscular atrophy (SMA) were able to swallow and feed orally after 12 months of treatment.
The Phase II study of Evrysdi showed significant improvements in…
The Phase II study of Evrysdi showed significant improvements in survival and motor milestones in babies with type 1 spinal muscular atrophy (SMA).
The European Commission has granted marketing authorisation to Roche’s Evrysdi™…
The European Commission has granted marketing authorisation to Roche’s Evrysdi™ (risdiplam) as a treatment for spinal muscular atrophy in infants, children and adults.
